logo

For the Inventor, By the Inventor

Talence, France

Gisele Prat

This inventor holds 18 USPTO granted patents. Top assignees: Societe Cortial, S.a., Laboratoires Sarget, Societe Cortial. Active years: 1978-1989.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gisele Prat. Retrieved from https://idiyas.com/inventor/gisele-prat

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18

% Patents Active = 100.0

Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 65(Granted Patents)


Company Filing History:

goldMedal10 out of 12 
 
Societe Cortial, S.a.
 patents
silverMedal6 out of 8 
 
Laboratoires Sarget
 patents
bronzeMedal2 out of 3 
 
Societe Cortial
 patents

Years Active: 1978-1989

Loading Chart...
18 patents (USPTO):Explore Patents
1. 4818772 - Derivatives of 4-aminoethoxy-5-isopropyl-2-methylbenzenes: methods of (1989-04-04),
2. 4758561 - N-substituted 2-aminomethylene-1,3-indanediones for treating arterial (1988-07-19),
3. 4757067 - Therapeutic application of N-substituted (1988-07-12),
4. 4721715 - Derivatives of 4-(arylpiperazinyl-ethylaminoethoxy) phenol useful for (1988-01-26),
5. 4698343 - (Alkoxy-2)phenylpiperazines having alpha-1 and beta blocking properties (1987-10-06),
6. 4605768 - 1-cycloalkylamino-3-t-butylamino-2-propanols, a method of preparing the (1986-08-12),
7. 4600788 - 4'-flavonecarboxylic acids and pharmaceutically acceptable derivatives (1986-07-15),
8. 4591600 - 3-hydroxyflavones: their preparation and therapeutic application (1986-05-27),
9. 4590193 - 3-(2-(4-phenylpiperazinylethyl)anilino)-isobenzofuranones, their method (1986-05-20),
10. 4499090 - N-(5-aminomethyl-2-oxazolin-2-yl)-N'-phenylureas, compositions and use (1985-02-12),
11. 4497812 - 2-Amino-5-aminomethyl-2-oxazolines, compositions and use (1985-02-05),
12. 4335113 - Triterpenic saponin having pharmacological potency (1982-06-15),
13. 4333938 - Imino derivatives of 5-aminobenzodioxole-1,3 which are useful as (1982-06-08),
14. 4333930 - Orthoarylideneaminophenethylamines and pharmaceutical compositions (1982-06-08),
15. 4211772 - Benzopyran glycoside acetals and ketals (1980-07-08),

Title: Gisele Prat: Innovator in Pharmaceutical Chemistry

Introduction

Gisele Prat is a prominent inventor based in Talence, France. She has made significant contributions to the field of pharmaceutical chemistry, holding a total of 18 patents. Her work focuses on developing innovative compounds with therapeutic applications.

Latest Patents

Among her latest patents, Gisele Prat has developed derivatives of 4-aminoethoxy-5-isopropyl-2-methylbenzenes. These compounds exhibit alpha 1-blocking activity and are characterized by specific structural formulas. Additionally, she has patented N-substituted 2-aminomethylene-1,3-indanediones, which are aimed at treating arterial conditions. These pharmaceutical compositions contain effective amounts of products with defined structural formulas, showcasing her expertise in medicinal chemistry.

Career Highlights

Throughout her career, Gisele Prat has worked with notable companies such as Société Cortial and Laboratoires Sarget. Her experience in these organizations has allowed her to refine her skills and contribute to various innovative projects in the pharmaceutical industry.

Collaborations

Gisele has collaborated with esteemed colleagues, including Claude Feniou and Marie-Hélène Creuzet. These partnerships have further enhanced her research and development efforts, leading to impactful advancements in her field.

Conclusion

Gisele Prat's contributions to pharmaceutical chemistry through her numerous patents and collaborations highlight her as a leading inventor in the industry. Her innovative work continues to pave the way for new therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…